003220.KO Daewon Pharmaceutical Co. Ltd.
- Market cap
- KRW 176B
- P/E
- 37.1x
- P/B
- 0.64x
- ROE
- 4.8%
- Dividend yield
- 3.66%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 003220.KO undervalued?
Graham number003220.KO trades 3.0% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Daewon Pharmaceutical Co. Ltd. fundamental analysis
No fundamental analysis for Daewon Pharmaceutical Co. Ltd. yet.
Daewon Pharmaceutical Co. Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Daewon Pharmaceutical Co. Ltd.
Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, manufactures and sells medicines and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis use. The company's principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product for pain relief; Freefol-MCT Inj., a microemulsion propofol for the anti-exogenous infectious bacteria; Megex-I Susp, a medicin…
Full company profileDaewon Pharmaceutical Co. Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Daewon Pharmaceutical Co. Ltd. annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 241B | 265B | 287B | 318B | 309B | 354B | 479B | 527B | 598B | 605B | 622B |
| Gross Profit | 138B | 152B | 165B | 180B | 166B | 176B | 238B | 257B | 287B | 273B | 292B |
| Operating Income | 29.1B | 25.3B | 30.7B | 35.1B | 24.1B | 19.4B | 43.0B | 32.2B | 28.2B | 3.51B | 8.85B |
| EBITDA | - | 32.4B | 41.7B | 47.5B | 40.5B | 37.0B | 61.8B | 48.0B | 45.6B | 33.5B | 50.6B |
| Net Income | 20.2B | 10.7B | 23.7B | 27.3B | 17.6B | 6.99B | 31.9B | 23.9B | 14.2B | -1.38B | 12.9B |
| EPS | - | 513 | 1,134 | 1,303 | 856 | 329 | 1,523 | 1,128 | 663 | -64 | 602 |
| Balance Sheet | |||||||||||
| Total Assets | 215B | 227B | 275B | 328B | 335B | 430B | 454B | 508B | 583B | 614B | 573B |
| Total Liabilities | 52.7B | 59.1B | 92.2B | 123B | 122B | 211B | 205B | 244B | 299B | 339B | 298B |
| Shareholders' Equity | 161B | 168B | 184B | 205B | 214B | 219B | 251B | 266B | 275B | 266B | 268B |
| Cash & Short-term Investments | 14.0B | 3.68B | 14.9B | 13.0B | 10.4B | 41.7B | 27.0B | 30.0B | 17.1B | 47.2B | 23.7B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 20.8B | 4.27B | 40.0B | 31.0B | 25.0B | 22.4B | 33.3B | 51.7B | 30.0B | 42.3B | 9.65B |
| Capital Expenditure | 20.6B | 14.7B | 40.8B | 33.0B | 11.3B | 4.10B | 13.4B | 20.6B | 53.6B | 42.1B | 30.8B |
| Free Cash Flow | - | -13.5B | -2.55B | -5.68B | 9.17B | 10.7B | 20.0B | 31.1B | -23.5B | 182M | -21.2B |
| Ratios | |||||||||||
| ROE | 12.5% | 6.4% | 12.9% | 13.3% | 8.2% | 3.2% | 12.7% | 9.0% | 5.2% | -0.5% | 4.8% |
| ROA | 9.4% | 4.7% | 8.6% | 8.3% | 5.3% | 1.6% | 7.0% | 4.7% | 2.4% | -0.2% | 2.2% |
| Net Profit Margin | 8.4% | 4.0% | 8.3% | 8.6% | 5.7% | 2.0% | 6.7% | 4.5% | 2.4% | -0.2% | 2.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Daewon Pharmaceutical Co. Ltd. dividends
- Dividend yield
- 3.66%
- Forward dividend
- 250.00 KRW
- Payout ratio
- -
- Ex-dividend date
- Dec 29, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 6.43B | 300 | - |
| 2024 | KRW 6.36B | 297 | 44.8% |
| 2023 | KRW 7.34B | 346 | 30.7% |
| 2022 | KRW 4.12B | 196 | 12.9% |
| 2021 | KRW 3.14B | 148 | 44.9% |
| 2020 | KRW 5.03B | 244 | 28.5% |
| 2019 | KRW 4.89B | 233 | 17.9% |
| 2018 | KRW 4.66B | 222 | 19.6% |
| 2017 | KRW 4.52B | 216 | 42.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.03:1 on Mar 7, 2022.
Who owns Daewon Pharmaceutical Co. Ltd.
- Insiders 37.71%
- Institutions 10.66%
- Public & others 51.63%
- Shares outstanding 21.4M
- Free float 13.0M
Daewon Pharmaceutical Co. Ltd. company profile
- Company name
- Daewon Pharmaceutical Co. Ltd.
- Ticker
- 003220.KO
- ISIN
- KR7003220001
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,236
- Fiscal year end
- December
- Address
- 386 Cheonhodae-ro, Seoul, South Korea
- Phone
- 82 2 2204 7000
- Website
- daewonpharm.com
About Daewon Pharmaceutical Co. Ltd.
Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, manufactures and sells medicines and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis use. The company's principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product for pain relief; Freefol-MCT Inj., a microemulsion propofol for the anti-exogenous infectious bacteria; Megex-I Susp, a medicine that supplements subalimentation of cancer patients; Trigel Susp, a therapy for gastritis and duodenal ulcer; and Renamezin Cap, a spherical carbonaceous adsorbent for chronic kidney disease. It also exports its products to approximately 40 countries primarily in Asia, Central and South America, the Middle East, CIS, and Africa. The company was founded in 1958 and is headquartered in Seoul, South Korea.
Daewon Pharmaceutical Co. Ltd. management
4- Mr. Seung-Ryel BaekVice Chairman & CEO · born 1959
- Jonathan In BaekCEO, President & Director
- Mr. Seil SonManaging Director · born 1968
- Mr. KyungJun LeeManaging Director · born 1965